Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ezabenlimab + afatinib
- Development stage
- Phase 2
- Lead developer
- Boehringer Ingelheim
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of ezabenlimab (BI-754091), a PD-1 immune checkpoint inhibitor, and afatinib, an irreversible ErbB family blocker that targets EGFR, HER2, and ErbB4. This combination is being investigated primarily for the treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) that has become refractory to at least one line of systemic treatment.
- Other names
- ezabenlimab and afatinibBI-754091 plus afatinibBI754091 plus afatinibBI 754091 plus afatinib
02
Targets
EGFR (Epidermal growth factor receptor)ERBB4 (Erb-b2 receptor tyrosine kinase 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ezabenlimab + afatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ezabenlimab + afatinib.